Africa CDC says it will talk to Merck about COVID pill, Pfizer talks 'advanced' - SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader.

2022-01-20 02:14:00 PM

Africa's top public health body plans to talk to Merck about obtaining supplies of its molnupiravir treatment pill for COVID-19, although talks with Pfizer about its Paxlovid medication were more advanced, it said on Thursday.

Covid 19

Africa’s top public health body plans to talk to Merck about obtaining supplies of its molnupiravir treatment pill for COVID-19, although talks with Pfizer about its Paxlovid medication were more advanced, it said on Thursday. covid19

Africa's top public health body plans to talk to Merck about obtaining supplies of its molnupiravir treatment pill for COVID-19, although talks with Pfizer about its Paxlovid medication were more advanced, it said on Thursday.

Image: ReutersAn experimental COVID-19 treatment pill, called molnupiravir is being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021.

Africa’s top public health body plans to talk to Merck about obtaining supplies of its molnupiravir treatment pill for COVID-19, although talks with Pfizer about its Paxlovid medication were more advanced, it said on Thursday.The Africa Centres for Disease Control and Prevention (CDC) had announced last week it was negotiating for supplies of Paxlovid, joining a global race for a drug seen as a potential game changer in fighting the virus.

Read more: SABC News »

Special Subscription Offer

Subscribe to the Mail & Guardian and get access to all our journalism and more, every day Read more >>

Landmark legal challenge against mandatory Covid vaccines in South AfricaTrade union Solidarity has launched a legal challenge against the University of the Free State (UFS) over its planned mandatory Covid-19 vaccine policy for staff and students.

MRNA booster shots such as Pfizer don’t block Omicron: South Africa studyBooster shots with mRNA vaccines such as those made by Pfizer and BioNTech failed to block infection with the omicron coronavirus variant in the first study of its kind, South African researchers said.

PODCAST: Vodacom CEO Shameel Joosub on mobile money in AfricaShameel Joosub spoke to FM columnist Toby Shapshak about the future of fintech in Africa

SA Vaccine Development | Medical manufacturing for AfricaPresident Cyril Ramaphosa is joining Health Minister Dr Joe Phaahla at the launch of the NantAfrica medical facility. 🙌🏽🙌🏽🙌🏽🙌🏽🙌🏽🇿🇦🇿🇦🇿🇦 Why are they bothering. The vaccine is no longer needed. Maybe older people need it but the rest nah

The best way to sell high-value properties in South AfricaSpecialised property brokerage In2Assets has revolutionised the sale of high-value properties in South Africa.

Twelve bouts to feature on ESPN Africa next weekESPN Africa will begin its quest to showcase the continent’s boxing talent to international audiences from next week.

@SABCNews Image: Reuters An experimental COVID-19 treatment pill, called molnupiravir is being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021.The union said it also plans to file several other court cases regarding mandatory vaccinations in the workplace.Seven German visitors to Cape Town experienced so-called breakthrough Covid-19 infections between late November and early December despite being boosted, the researchers, whose investigation was authorized by the University of Cape Town and Stellenbosch University, said in findings published in The Lancet on 18 January..

Africa’s top public health body plans to talk to Merck about obtaining supplies of its molnupiravir treatment pill for COVID-19, although talks with Pfizer about its Paxlovid medication were more advanced, it said on Thursday. The Africa Centres for Disease Control and Prevention (CDC) had announced last week it was negotiating for supplies of Paxlovid, joining a global race for a drug seen as a potential game changer in fighting the virus. These legal challenges are expected to act as some of the first ‘test cases’ and provide clarity around vaccine mandates in the public and business sectors. “We don’t have a preference to talk only to Pfizer and not Merck, it’s just that Pfizer has been more forthcoming with their engagement. The rapid global spread of omicron, first identified in Botswana and South Africa in late November, has spurred countries such as the U. We plan to engage both companies equally,” said John Nkengasong, the Africa CDC director. “As a result, we see dozens of employers exploiting this uncertainty and using it as an excuse to lay off employees without following the correct procedures,” said Solidarity chief executive Dr Dirk Hermann. “The Pfizer arrangement is far advanced … In time, if we narrow this down and finalise … with Pfizer, I’m sure we’ll engage with Merck as well,” he said at a news briefing.

The Paxlovid medication was nearly 90% effective in preventing hospitalisations and deaths, and data suggested it retains its effectiveness against the Omicron variant, Pfizer has said. “Meanwhile, we are seeing employees’ rights and livelihoods being threatened throughout South Africa.S. Merck has said it expects molnupiravir to be effective against the highly contagious Omicron, which has driven a surge in cases across the world. While vaccines have been governments’ main weapon against COVID, there are hopes Merck and Pfizer’s experimental pills – taken at home rather than in hospital or medical centres – could be key in reducing the chances of dying or hospitalisation for those most at risk of severe illness. We must obtain legal certainty. Nearly 30 generic drugs manufacturers signed an agreement to produce low-cost versions of molnupiravir, the United Nations-backed Medicines Patent Pool said on Thursday. The Germans, four of whom were participating in training at Cape Town hospitals and three of whom were on vacation, were between the ages of 25 and 39, according to the researchers. This entry was posted on 20 Jan 2022,12:49PM at 12:49 PM and is filed under . According to Solidarity, any form of “blanket approach” that does not take into account the unique situation of individual employees or students will be illegal and also undesirable.